Future Pak, LLC

Privately held: no public share price

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Crofelemer(Mytesi)
Approved
Chloride channel (intestinal epithelium)Small molecule
Short Bowel SyndromeHIV-Associated Diarrhea

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Crofelemer · MytesiPhase 2/3Microvillus Inclusion Disease, Congenital Disorders, Rare Diseases
Est. primary completion 2026-12 · NCT06721871 · CT.gov ↗
What to watch
2027 (1)
March 2027 (1)
Crofelemer · MytesiPhase 2Short Bowel Syndrome, Malabsorption Syndromes, Short Gut Syndrome, Post-Op Complication, Functional Gastrointestinal Disorders
Est. primary completion 2027-03 · NCT06904872 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 July 2024Topline resultCrofelemerPhase 3 OnTarget: primary endpoint not met across all tumor types

Financial reports

No financial reports recorded.